A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels by Shinji Yamazaki

Connect to this object online.

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition by Shinji Yamazaki, Raymond Evers, Loeckie De Zwart

Connect to this object online.

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?... by Shinji Yamazaki, Raymond Evers, Loeckie De Zwart

Connect to this object online.

Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition by Shinji Yamazaki, Raymond Evers, Loeckie De Zwart

Connect to this object online.

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B by Shinji Nakayama, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, Yuichi Sugiyama

Connect to this object online.

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein-cytochrome P450 3A4 dual s... by Xian Pan, Shinji Yamazaki, Sibylle Neuhoff, Mian Zhang, Venkatesh Pilla Reddy

Connect to this object online.

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction by Shinji Yamazaki, Chester Costales, Sarah Lazzaro, Soraya Eatemadpour, Emi Kimoto, Manthena V. Varma

Connect to this object online.

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling by Chester Costales, Jian Lin, Emi Kimoto, Shinji Yamazaki, James R. Gosset, A. David Rodrigues, Sarah Lazzaro, Mark A. West, Michael West, Manthena V. S. Varma

Connect to this object online.